Let’s look at three doctors in particular. Their names are Dr. Diane Ehrensaft, Stephen Rosenthal, and Johanna Olson. Why?
All three of those names have had a financial relationship with AbbVie, maker of Androgel and Lupron, amongst other hormone replacement therapies and GnRH agonists. All three have gone on to promote the off-label use of AbbVie products to treat transgenderism. Both Joanna Olson and Diane Ehrensaft attended an AbbVie advisory board on gender care, Olson in 2015 and Ehrensaft in 2014. Olson discloses this as a conflict of interest in the paperCare of a Transgender Adolescent Commentary, which was published July 2015 — she attended this advisory board after submission and was compensated for attending. Olson then continued promoting off-label use of AbbVie drugs. Diane Ehrensaft does not declare this as a conflict of interest on any research papers, but it appears in her Curriculum Vitae (scroll to page 16), which she submitted to court while an expert witness, and is hosted on her website. Her CV reports, that in 2014, she was a board member of the ‘AbbVie Trans Advisory Board’, while promoting their drugs for off-label use in transgenderism, both in academia and through popular science books she wrote, such as The Gender Creative Child. Was she compensated for being on this advisory board, like Olson? Stephen Rosenthal frequently discloses that he is a consultant for AbbVie as a conflict of interest in both interviews and research, and then continues to promote the dangerous off-label use of their medication in adolescents.